Article Text

Download PDFPDF
Gynecologic Cancer Intergroup (GCIG) Consensus Review for Ovarian Germ Cell Tumors
  1. Jubilee Brown, MD*,
  2. Michael Friedlander, MBChB, FRACP, PhD,
  3. Floor J. Backes, MD,
  4. Philipp Harter, MD§,
  5. Dennis M. O’Connor, MD,
  6. Thibault de la Motte Rouge, MD,
  7. Domenica Lorusso, MD#,
  8. Johanne Maenpaa, MD**,
  9. Jae-Weon Kim, MD, PhD,,
  10. Meghan E. Tenney, MD, and
  11. Michael J. Seckl, PhD, FRCP§§
  1. *University of Texas MD Anderson Cancer Center, Houston, TX (Gynecologic Oncology Group [GOG]);
  2. Prince of Wales Hospital, Sydney, Australia (Australia and New Zealand Gynecological Oncology Group [ANZGOG]);
  3. The Ohio State University, Columbus, OH (GOG);
  4. §Kliniken Essen-Mitte, Essen, Germany (AGO);
  5. University of Louisville, Louisville, KY (GOG);
  6. Institut Curie, Hôpital Rene Huguenin, Saint Cloud, France (Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens [GINECO]);
  7. #Fondazione IRCCS National Cancer Institute of Milan, Italy (Multicentre Italian Trials in Ovarian Cancer);
  8. **Tampere University Hospital, Tampere, Finland (Nordic Society of Gynaecological Oncology);
  9. ††Seoul National University College of Medicine, Seoul, Korea (Korean Gynecologic Oncology Group);
  10. ‡‡The University of Chicago, Chicago, IL (GOG); and
  11. §§Charing Cross Hospital, London, UK (Medical Research Council/National Cancer Research Institute [MRC NCRI]).
  1. Address correspondence and reprint requests to Jubilee Brown, MD, Department of Gynecologic Oncology and Reproductive Medicine, 1155 Herman Pressler Blvd, Unit 1362, Houston, TX 77030. E-mail: jbbrown{at}


Abstract Most women diagnosed with malignant ovarian germ cell tumors have curable disease and experience excellent survival with manageable treatment-associated morbidity, related both to tumor biology and improvements in treatment over the last 4 decades. Malignant ovarian germ cell tumors occur predominantly in girls, adolescents, and young women and are often unilateral tumors of early stage, although advanced-stage disease occurs in approximately 30% of patients. Tumors are usually chemosensitive, thereby allowing fertility-sparing surgery in most women with high chance of cure. Differences in practice do exist among providers in various subspecialties and geographic areas. In most settings, collaborative efforts among specialties allow the optimal treatment of women with these rare tumors, and implementation of standard guidelines at an international level should translate to effective clinical trial design, rapid accrual to clinical trials, and universally improved patient outcomes.

This consensus guideline represents a summary of recommendations for diagnosis and management that has been agreed upon by cooperative groups worldwide. It builds upon individual publications including previously published summary documents and provides the most current practice standards validated worldwide.

  • Germ cell tumors
  • Bleomycin
  • Etoposide
  • Cisplatin

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • No funding sources were present.

  • The authors declare no conflicts of interest.